Tüdőrák: vizsgálatok itt: Németország
182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Where
- Düsseldorf, Frankfurt am Main, Freiburg im Breisgau
- Életkor
- 18 év and over
- People
- 162 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227298 · EU 2025-523526-40-00 - 2. fázisTaking peopleSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Where
- Duesseldorf, Grosshansdorf, Homburg, Jena, Luebeck
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Grosshansdorf, Halle (saale), Hamburg, Hanover, Heidelberg, Homburg, Immenhausen, Karlsruhe, Leipzig, Loewenstein, Luebeck, Mannheim, Muenster, Munich, Oldenburg, Regensburg, Tuebingen, Wuerzburg
- Életkor
- 18 év and over
- People
- 282 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 - 2. fázisTaking peopleA Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- Where
- Dresden, Giessen, Kassel, Regensburg
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05967689 - 1/2. fázisVisszavonvaStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Bayern, Berlin, Heidelberg, Mainz
- Életkor
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - 1/2. fázisTaking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Mannheim, Regensburg
- Életkor
- 18 év to 130 év
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - 2/3. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Cologne, Giessen, Hamburg, Heidelberg, Jena, Wuerzburg
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 3. fázisNot yet taking people in NémetországEffect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
- Where
- Berlin, Bochum, Goettingen
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Pharmacosmos A/S
See details and how to joinNCT07473128 · EU 2025-525026-35-00 - 1. fázisTaking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
- Életkor
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - 1/2. fázisTaking peopleA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Where
- Heidelberg, Tuebingen
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00 - 3. fázisTaking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Berlin, Esslingen am Neckar, Grosshansdorf, Immenhausen, Munich, Velbert
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - No phaseTaking peopleNIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
- Where
- Bad Homburg, Berlin, Bremen, Celle, Chemnitz, Cologne, Deggendorf, Frankfurt, Georgsmarienhütte, Gera, Goslar, Greifswald, Halle-Dolau, Hanover, Herne, Hösbach, Koblenz, Koln-Mehrheim, Mainz, Marburg, Münnerstadt, Neuss, Offenbach, Querfurt, Ravensburg, Rüsselsheim am Main, Treuenbrietzen, Ulm, Wiesbaden, Zwickau
- Életkor
- 18 év to 120 év
- People
- 600
- Run by
- AstraZeneca
See details and how to joinNCT06494540 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Where
- Amberg, Augsburg, Bad Saarow, Berlin, Bonn, Brunswick, Essen, Flensburg, Hamburg, Heidelberg, Immenhausen, Koblenz, Leipzig, Loewenstein, Munich, Offenbach Am Main, Oldenburg, Schweinfurt, Trier, Velbert, Wuerzburg, Wuppertal
- Életkor
- 18 év and over
- People
- 830 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00 - 4. fázisTaking peopleA Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy
- Where
- Heidelberg
- Életkor
- 18 év and over
- People
- 550 worldwide
- Run by
- Intuitive Surgical
See details and how to joinNCT07761351 - 1/2. fázisTaking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- Cologne
- Életkor
- 12 év and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - 3. fázisTaking peopleA Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Where
- Cologne, Dresden, Essen, Freiburg im Breisgau, Gauting, Greifswald, Grosshansdorf, Heidelberg, Kassel, Minden, Regensburg, Stuttgart, Wuerzburg
- Életkor
- 18 év and over
- People
- 531 worldwide
- Run by
- AbbVie
See details and how to joinNCT07365241 · EU 2025-523819-11-00 - 1. fázisTaking peopleA study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
- Where
- Berlin, Cologne, Dresden, Frankfurt Am Main, Heidelberg, Immenhausen, Moers
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Revolution Medicines Inc.
See details and how to join2023-509572-42-00 - 1/2. fázisTaking peopleStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Cologne, Esslingen am Neckar, Moers, Nuremberg
- Életkor
- 18 év and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551 - 1. fázisNot yet taking people in NémetországPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Essen, Munich
- Életkor
- 18 év to 100 év
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - 3. fázisTaking peopleClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Where
- Chemnitz, Cologne, Erlangen, Esslingen, Gauting, Giessen, Goettingen, Halle (saale), Hanover, Herne, Karlsruhe, Minden, Moers, Stuttgart
- Életkor
- 18 év and over
- People
- 780 worldwide
- Run by
- Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00 - 2. fázisTaking peopleA Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Where
- Cologne, Frankfurt Am Main, Halle (saale), Munich, Wuerzburg
- Életkor
- 18 év and over
- People
- 182 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00 - 1. fázisTaking peopleA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Essen
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 - 3. fázisTaking peoplePhase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
- Where
- Berlin, Chemnitz, Cologne, Gauting, Grosshansdorf, Heidelberg, Kiel, Luebeck
- Életkor
- 18 év and over
- People
- 168 worldwide
- Run by
- Amgen Inc.
See details and how to join2026-525489-23-00 - No phaseTaking peopleORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Where
- Hamburg, Heilbronn, Munich
- Életkor
- 18 év and over
- People
- 2285 worldwide
- Run by
- Guardant Health, Inc.
See details and how to joinNCT05059444